Search research articles
Contact Us
Filters
Showing results (111-120 of 212) with videos related to
Page
of 22
Sort By:
Oncotarget
|
December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
Parisa Momtaz, James J Harding, Charlotte Ariyan, et al.
Seminars in Nuclear Medicine
|
February 18, 2025
Artificial Intelligence for Drug Discovery: An Update and Future Prospects
Harrison J Howell, Jeremy P McGale, Aurélie Choucair, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Cancer Immunology Research
|
May 22, 2014
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes
Shigehisa Kitano, Michael A Postow, Carly G K Ziegler, et al.
The Oncologist
|
February 6, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, et al.
Cancer Medicine
|
February 23, 2018
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Samuel Rosner, Erica Kwong, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2020
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner, Jessica S Palmer, Alexander N Shoushtari, et al.
Melanoma Research
|
January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
Alexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
Annals of Surgical Oncology
|
December 19, 2019
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
Danielle M Bello, Katherine S Panageas, Travis Hollmann, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 212) with videos related to
Sort By:
Page
of 22
Oncotarget
|
December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
Parisa Momtaz, James J Harding, Charlotte Ariyan, et al.
Seminars in Nuclear Medicine
|
February 18, 2025
Artificial Intelligence for Drug Discovery: An Update and Future Prospects
Harrison J Howell, Jeremy P McGale, Aurélie Choucair, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Cancer Immunology Research
|
May 22, 2014
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes
Shigehisa Kitano, Michael A Postow, Carly G K Ziegler, et al.
The Oncologist
|
February 6, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, et al.
Cancer Medicine
|
February 23, 2018
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Samuel Rosner, Erica Kwong, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2020
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner, Jessica S Palmer, Alexander N Shoushtari, et al.
Melanoma Research
|
January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
Alexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
Annals of Surgical Oncology
|
December 19, 2019
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
Danielle M Bello, Katherine S Panageas, Travis Hollmann, et al.
Page
of 22